Home › Companies › IMUX

Immunic

Market cap $116M 15.9M shares (10-Q, Nov 6, 2026) × $7.33 close Nov 17, 2026

Most recent annual filing: 2026-02-26

Catalyst timeline

7 trackedQuarter catalyst calendar →
  1. vidofludimus calcium readout2026vidofludimus calcium readout, 2026, notable
  2. vidofludimus calcium PPMS Ph3 start2H 2026vidofludimus calcium PPMS Ph3 start, 2H 2026, routine
  3. vidofludimus calcium Ph3 toplineDec 2026vidofludimus calcium Ph3 topline, Dec 2026, thesis-defining
  4. ENSURE-1/ENSURE-2 toplineDec 2026ENSURE-1/ENSURE-2 topline, Dec 2026, material
  5. PROTECT-MS trial start1H 2027PROTECT-MS trial start, 1H 2027, routine
  6. vidofludimus calcium RMS NDA filingMid-2027vidofludimus calcium RMS NDA filing, Mid-2027, material
  7. vidofludimus calcium RMS FDA approval2028vidofludimus calcium RMS FDA approval, 2028, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Technology platforms

Nurr1 platform

Nuclear receptor-related 1 (Nurr1) activation platform comprising next-generation small molecule derivatives (IMU-381 series) targeting neurologic, gastrointestinal, and autoimmune diseases

Targets: Nurr1

Capital (as filed)

Cash
$132M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$28.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$132M cash, runway late 2027 per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (3)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (3 calls)

Every verdict Biotech Distilled has published on Immunic, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Immunic, Inc. (IMUX) — Scientific Deep Dive for Vidofludimus Calcium (IMU-838) and Pipeline Products Strong smart-money signal and a credible binary catalyst inside 12 months are offset by a Phase 2 PMS primary miss, generic Aubagio as the pricing floor, fenebrutinib positive Phase 3 in both indications, and a heavy warrant and royalty stack; wait for ENSURE readouts before committing capital.
  2. Watch UPDATE: Immunic (IMUX) - The Founder Is Gone and the Auditors Priced a Sale at 50/50 Watch list maintained as the setup is clearer — runway confirmed, commercial bench complete, founder transition finished — but the stock at $15.48 is 77% above the smart-money PIPE mark, compressing the original asymmetry, while fenebrutinib, generic Aubagio, and the royalty stack remain unchanged.
  3. Speculative buy speculative UPDATE: Immunic (IMUX) - Back Below the Smart-Money Line Stock has fallen below the $8.73 smart-money PIPE mark weeks before the December ENSURE readout, restoring the original accumulate-below-$8.73 logic; the primary endpoint is meaningfully de-risked by EMPhASIS Phase 2 data, but any position should be sized for a total loss on a miss.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (36)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 10, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

23 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)